These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16198656)

  • 1. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
    Shao H; Ren XM; Liu NF; Chen GM; Li WL; Zhai ZH; Wang DW
    J Clin Pharm Ther; 2010 Jun; 35(3):351-60. PubMed ID: 20831536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.
    Tan B; Zhang YF; Chen XY; Zhao XH; Li GX; Zhong DF
    Eur J Clin Pharmacol; 2010 Feb; 66(2):145-51. PubMed ID: 19847408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
    Zhang Y; Si D; Chen X; Lin N; Guo Y; Zhou H; Zhong D
    Br J Clin Pharmacol; 2007 Jul; 64(1):67-74. PubMed ID: 17298483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
    Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
    Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
    Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
    Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
    Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
    Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
    Zhang YF; Chen XY; Guo YJ; Si DY; Zhou H; Zhong DF
    Yao Xue Xue Bao; 2005 Sep; 40(9):796-9. PubMed ID: 16342679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
    Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
    Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
    Bogman K; Silkey M; Chan SP; Tomlinson B; Weber C
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1005-15. PubMed ID: 20549497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.